DE69833727D1 - Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C - Google Patents

Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C

Info

Publication number
DE69833727D1
DE69833727D1 DE69833727T DE69833727T DE69833727D1 DE 69833727 D1 DE69833727 D1 DE 69833727D1 DE 69833727 T DE69833727 T DE 69833727T DE 69833727 T DE69833727 T DE 69833727T DE 69833727 D1 DE69833727 D1 DE 69833727D1
Authority
DE
Germany
Prior art keywords
activated protein
vascular disease
treating vascular
treating
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833727T
Other languages
English (en)
Other versions
DE69833727T2 (de
Inventor
Brian William Grinnell
Daniel Charles Howey
Jackson Charles Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69833727D1 publication Critical patent/DE69833727D1/de
Publication of DE69833727T2 publication Critical patent/DE69833727T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
DE69833727T 1997-03-24 1998-03-24 Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C Expired - Lifetime DE69833727T2 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4253397P 1997-03-24 1997-03-24
US42533P 1997-03-24
US6254997P 1997-10-20 1997-10-20
US62549P 1997-10-20
US6476597P 1997-11-07 1997-11-07
US64765P 1997-11-07

Publications (2)

Publication Number Publication Date
DE69833727D1 true DE69833727D1 (de) 2006-05-04
DE69833727T2 DE69833727T2 (de) 2006-08-31

Family

ID=27366150

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833727T Expired - Lifetime DE69833727T2 (de) 1997-03-24 1998-03-24 Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C

Country Status (19)

Country Link
EP (1) EP0872245B1 (de)
JP (1) JP4680329B2 (de)
KR (1) KR20010005626A (de)
CN (1) CN1168492C (de)
AT (1) ATE319472T1 (de)
AU (1) AU733756B2 (de)
BR (1) BR9808063A (de)
CA (1) CA2284279A1 (de)
DE (1) DE69833727T2 (de)
EA (1) EA199900862A1 (de)
ES (1) ES2257794T3 (de)
ID (1) ID23176A (de)
IL (1) IL131615A0 (de)
NO (1) NO994630D0 (de)
NZ (1) NZ337291A (de)
PL (1) PL335802A1 (de)
TR (1) TR199902335T2 (de)
TW (1) TW513307B (de)
WO (1) WO1998042358A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1128842B1 (de) * 1998-11-13 2006-03-15 Eli Lilly And Company Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
JP2004508280A (ja) * 2000-02-04 2004-03-18 ザ　スクリップス　リサーチ　インスティテュート 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用
ES2504365T3 (es) * 2002-12-05 2014-10-08 Zz Biotech L.L.C. La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante
CN100451033C (zh) * 2005-01-11 2009-01-14 北京诺赛基因组研究中心有限公司 抑制人体转录因子ap-1的基因及其编码多肽和用途
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
US11217526B2 (en) 2019-02-28 2022-01-04 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with source resistor and manufacturing method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物

Also Published As

Publication number Publication date
CN1168492C (zh) 2004-09-29
NZ337291A (en) 2001-05-25
KR20010005626A (ko) 2001-01-15
TW513307B (en) 2002-12-11
CN1252726A (zh) 2000-05-10
ES2257794T3 (es) 2006-08-01
NO994630L (no) 1999-09-23
EA199900862A1 (ru) 2000-04-24
WO1998042358A1 (en) 1998-10-01
CA2284279A1 (en) 1998-10-01
JP2001518933A (ja) 2001-10-16
DE69833727T2 (de) 2006-08-31
BR9808063A (pt) 2000-06-06
AU6474198A (en) 1998-10-20
AU733756B2 (en) 2001-05-24
IL131615A0 (en) 2001-01-28
ATE319472T1 (de) 2006-03-15
EP0872245B1 (de) 2006-03-08
TR199902335T2 (xx) 2000-01-21
PL335802A1 (en) 2000-05-22
NO994630D0 (no) 1999-09-23
JP4680329B2 (ja) 2011-05-11
ID23176A (id) 2000-03-23
EP0872245A1 (de) 1998-10-21

Similar Documents

Publication Publication Date Title
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE280577T1 (de) Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
DE69435243D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
ATE175348T1 (de) L - deprenyl zur behandlung von makulärer degeneration
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
DE69532066D1 (de) Arzneimittel zur Behandlung von Restenosis und Gefässsklerose
DE69225754D1 (de) Verfahren zur Behandlung von wasserunlöslichen Superabsorbensmaterialien
DE69833727D1 (de) Verfahren zur Behandlung der Gefässerkrankungen mit aktiviertem Protein C
DE69519602T2 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE3878529D1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
DE69430807T2 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE69133542D1 (de) Katheter zur Behandlung von Prostaterkrankungen
ATE85750T1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
ATA157396A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATA17797A (de) Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
ATE72979T1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN